Eli Lilly Accelerates Drug Discovery with AI Partnerships, RLT Deals Rise 3.5x
LLY•Eli Lilly inked AI partnerships with OpenAI and Nvidia to accelerate drug discovery while reporting a 3.5-fold rise in Q1 radiopharmaceutical deals versus 2025 and advancing alpha-emitter RLTs with encouraging Phase I results. Under CEO Dave Ricks, GLP-1 sales continue to drive cash flow that funds targeted acquisitions and R&D.
1. AI Partnerships Fuel Discovery
Eli Lilly formalized collaborations with OpenAI and Nvidia to integrate generative AI and advanced compute into its drug discovery platform. These deals aim to shorten lead optimization timelines and identify novel targets across oncology and metabolic disease projects, potentially accelerating later-stage candidate nominations.
2. Surge in Radiopharmaceutical Deals
In Q1 2026, Lilly and other industry players inked radioligand therapy partnerships and licensing agreements valued 3.5 times higher than Q1 2025. The company is exploring alpha-emitter compounds like actinium-225 PSMA-617, following encouraging safety and efficacy signals in Phase I metastatic prostate cancer trials.
3. GLP-1 Profits Support Growth
Under CEO Dave Ricks, Lilly’s GLP-1 portfolio continues to generate robust cash flow, exceeding prior-year growth rates. Management is redeploying these proceeds into strategic acquisitions, expansion of weight-loss indications and bolstering R&D for next-generation therapies.
